Select publications

Agarwal MM et al. Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy. Cancer 2005;103(10):2042-52. Abstract

Boccardo F et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 2005;23(4):808-15. Abstract

Perdona S et al. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: A randomised controlled trial. Lancet Oncol 2005;6(5):295-300. Abstract

Petrylak DP et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-20. Abstract

Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of the randomized trials. Lancet 2000;355(9214):1491-8. Abstract

Saltzstein D et al. Prevention and management of bicalutamide-induced gynecomastia and breast pain: Randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis 2005;8(1):75-83. Abstract

Schellhammer PF et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. Urology 1997;50(3):330-6. Abstract

Shahinian VB et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352(2):154-64. Abstract

Smith MR et al. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: Effects on bone mineral density and body composition. J Clin Oncol 2004;22(13):2546-53. Abstract

Smith MR et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169(6):2008-12. Abstract

Tannock IF et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12. Abstract

Wirth MP et al; Casodex Early Prostate Cancer Trialists’ Group. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: Results from the second analysis of the early prostate cancer program at median follow-up of 5.4 years. J Urol 2004;172(5 Pt 1):1865-70. Abstract